Enanta ends internal work with NASH FXR agonists
US biotech Enanta Pharmaceuticals (Nasdaq: ENTA) has delivered an update on its two clinical stage farnesoid X receptor (FXR) agonists, EDP-305 and EDP-297, in non-alcoholic steatohepatitis (NASH).
A pre-planned interim analysis of a subset of patients through week 12 in the Phase IIb ARGON-2 trial of EDP-305 as a monotherapy and data from its Phase I clinical study of EDP-297 provided meaningful information on dose selection and characterization for these compounds.
"A combination approach with FXR agonists will ultimately provide the optimal treatment regimen"This has allowed Enanta to make a business decision to prioritize combination approaches through an out-licensing strategy for further development of these two programs, and the company has said that it does not plan to continue further development internally.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze